AR113993A1 - Formulación una vez al día de hidrosmina - Google Patents

Formulación una vez al día de hidrosmina

Info

Publication number
AR113993A1
AR113993A1 ARP180103740A ARP180103740A AR113993A1 AR 113993 A1 AR113993 A1 AR 113993A1 AR P180103740 A ARP180103740 A AR P180103740A AR P180103740 A ARP180103740 A AR P180103740A AR 113993 A1 AR113993 A1 AR 113993A1
Authority
AR
Argentina
Prior art keywords
hydrosmine
day
pharmaceutical composition
calcium
modified release
Prior art date
Application number
ARP180103740A
Other languages
English (en)
Inventor
Esperanza Beascoa-Alzola
Urlanga Lorena Gonzlez
Garca Tania Gonzlez
Azpitarte Ignacio Ortega
Herrero Gonzalo Hernndez
Bulln Alejandro Vicente
De Campo Nria Montes
Negre Jos Mara Su
Pujol Francisco Gual
Carreras Manuel Roig
Ricart Anna Nardi
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of AR113993A1 publication Critical patent/AR113993A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Composición farmacéutica de liberación modificada caracterizada porque comprende: (i) desde 200 mg hasta 1200 mg de hidrosmina; (ii) al menos un glicérido, que consiste en un éster derivado de glicerol y de uno a tres ácidos grasos; y (iii) al menos un diluyente seleccionado de celulosa microcristalina silicificada, celulosa, celulosa microcristalina, maltosa, carbonato de calcio, carbonato de magnesio, óxido de magnesio, fosfato de calcio, hidrogenofosfato de calcio, croscarmelosa sódica, crospovidona, glicolato sódico de almidón, sacarosa, o mezclas de los mismos. Reivindicación 13: Composición farmacéutica de liberación modificada obtenible mediante el método según la reivindicación 12.
ARP180103740A 2017-12-21 2018-12-19 Formulación una vez al día de hidrosmina AR113993A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17382877 2017-12-21

Publications (1)

Publication Number Publication Date
AR113993A1 true AR113993A1 (es) 2020-07-08

Family

ID=60923332

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103740A AR113993A1 (es) 2017-12-21 2018-12-19 Formulación una vez al día de hidrosmina

Country Status (15)

Country Link
EP (1) EP3727345A1 (es)
AR (1) AR113993A1 (es)
BR (1) BR112020012437A2 (es)
CL (1) CL2020001697A1 (es)
CO (1) CO2020008721A2 (es)
CR (1) CR20200320A (es)
EA (1) EA202091535A1 (es)
EC (1) ECSP20041796A (es)
MX (1) MX2020006505A (es)
NI (1) NI202000049A (es)
PE (1) PE20210458A1 (es)
PH (1) PH12020550926A1 (es)
SG (1) SG11202005652YA (es)
UY (1) UY38026A (es)
WO (1) WO2019122051A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011143118A2 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcohol-resistant formulations
WO2017062027A1 (en) 2015-10-09 2017-04-13 Bayer Healthcare Llc Modified release formulation of naproxen sodium

Also Published As

Publication number Publication date
BR112020012437A2 (pt) 2020-11-24
CO2020008721A2 (es) 2020-12-10
WO2019122051A1 (en) 2019-06-27
PE20210458A1 (es) 2021-03-08
UY38026A (es) 2019-07-31
ECSP20041796A (es) 2020-10-30
NI202000049A (es) 2020-11-24
EA202091535A1 (ru) 2020-09-11
PH12020550926A1 (en) 2021-05-31
CL2020001697A1 (es) 2020-11-27
SG11202005652YA (en) 2020-07-29
MX2020006505A (es) 2020-09-17
EP3727345A1 (en) 2020-10-28
CR20200320A (es) 2020-12-14

Similar Documents

Publication Publication Date Title
AR098746A1 (es) Composiciones farmacéuticas que comprenden fumarato de dimetilo, uso, método
CL2023000767A1 (es) Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto.
AR100187A1 (es) Composición farmacéutica que contiene un inhibidor de alk (quinasa de linfoma anaplásico)
AR118273A2 (es) Excipiente estabilizante para una vacuna de virus completo inactivado
WO2005079853A3 (en) Soft gelatin capsule comprising omega-3 polyunsaturated fatty acid
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
MX2018015302A (es) Esteres de acidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y metodos para usar los mismos.
ECSP18014922A (es) Composiciones de insulina de rápida acción
CL2019000573A1 (es) Composiciones para comprimidos.
NZ600271A (en) Lyophilization methods, compositions, and kits
MX2017016823A (es) Composiciones orales que contienen éster de 17- hydroxiprogesterona y métodos relacionados.
PE20130063A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
WO2019073331A3 (en) Pharmaceutical compositions of apremilast
MX2014004710A (es) Composiciones farmaceuticas que comprenden dgla y/o 15-hetre y metodos para usar los mismos.
WO2016038521A8 (en) Pharmaceutical compositions of liraglutide
CL2015002832A1 (es) Formulación farmaceutica que comprende fosfatidilcolina para el tratamiento de colitus ulcerosa.
EA201890944A1 (ru) Фармацевтические композиции нилотиниба гидрохлорида
AR113993A1 (es) Formulación una vez al día de hidrosmina
MX2018005786A (es) Formulaciones novedosas.
PH12017501081B1 (en) Novel pharmaceutical composition
AR087371A1 (es) Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos
JOP20170197B1 (ar) الصيغة الجديدة التي تشتمل على مشتق بنزيميدازول
PH12017500269A1 (en) Composite formulation for oral administration comprising omega-3 fatty acid esters and statins
MX2019001771A (es) Composición farmacéutica sólida que comprende el sofosbuvir amorfo.
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer

Legal Events

Date Code Title Description
FB Suspension of granting procedure